News | June 12, 2014

Philips Vereos Digital PET/CT Has Improved Detector Performance

First digital PET/CT scanner joins suite of molecular imaging solutions

June 12, 2014 — Philips Healthcare recently introduced Vereos PET/CT, the first digital PET/CT (positron emission tomography/computed tomography) scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. In addition to Vereos, Philips showcased a selection of molecular imaging solutions designed to deliver high image quality, critical clinical information and greater connectivity.

The Vereos PET/CT uses digital silicon photomultiplier detectors instead of traditional analog detectors, creating a step change in performance that includes approximately two-times increase in sensitivity gain, volumetric resolution and quantitative accuracy compared to analog systems. These improvements can ultimately be translated into high image quality, increased diagnostic confidence, improved treatment planning and faster workflows.

"From connected devices to data-driven insights, the pace of imaging innovation is allowing us to see more," said Gene Saragnese, chief executive officer, Imaging Systems, Philips. "Molecular imaging technology is leading the way with digital detection and advanced visualization built on insights from those at the heart of care."

Visitors to the Philips booth at SNMMI had the opportunity to interact with Vereos digital PET/CT clinical images and technology using engaging 3-D visualization tools. The experience provided clinicians an understanding of how Vereos can be used to deliver customized care to meet their most pressing needs.

During the SNMMI annual meeting, Philips also hosted a series of three "Innovation Talks" in its booth theater area, spotlighting customers, scientists and industry thought leaders who discussed topics related to the current and future landscape for digital PET, patient-centered imaging and the importance of creating customized workflows to help manage patient care and radiation dose.

Other advanced molecular imaging technology solutions showcased include”

  • iPatient: An advanced platform with an intuitive interface, iPatient helps to facilitate patient-centered imaging, allows for efficient communication between the CT system and injector, and aids in the delivery of appropriate contrast dose and consistent image quality.
  • BrightView XCT: A SPECT/CT system designed entirely for nuclear medicine, BrightView XCT enables low patient dose levels, high-resolution localization and high-quality attenuation correction, for smart assessments and short exams with the patient's comfort in mind.
  • IntelliSpace Portal: Part of Philips' family of clinical information systems within Philips Healthcare’s Informatics Solutions and Services Group, the IntelliSpace Portal offers extensive clinical coverage, streamlined workflow and continuous evolution of advanced visualization and analysis capabilities within a single solution.

For more information: www.philips.com/snmmi

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init